SpyGlass Pharma Unveils Promising 18-Month Data from First-in-Human Study of Glaucoma Drug Delivery Platform
SpyGlass Pharma presented 18-month follow-up data today from its first-in-human study of patients with glaucoma or ocular hypertension. The study evaluated the efficacy of the SpyGlass IOL-based drug delivery platform, which was implanted during cataract surgery. The results were shared at Eyecelerator, ahead of the American Academy of Ophthalmology annual meeting.
The study involved 23 patients who underwent cataract surgery while also receiving the SpyGlass Drug Delivery Platform. Over the 18 months, the platform delivered consistent and sustained reductions in IOP across all three dose strengths. The mean reduction in IOP was 43.7% compared to baseline, and all patients were able to remain off topical IOP-lowering medications throughout the follow-up period.
In the study, 100% of patients achieved an IOP reduction of more than 20% from baseline, with 96% maintaining IOP levels of ≤18 mmHg at the 18-month mark. The SpyGlass platform demonstrated a strong safety profile, with no product-related adverse events reported, according to a company news release.
“The clinical results achieved by the SpyGlass Drug Delivery Platform, now 18 months post-implantation, continue to be compelling for ophthalmic surgeons and for patients living with glaucoma," Malik Kahook, MD, Co-founder of SpyGlass Pharma, said in the news release. "Long-term drug delivery of trusted medicine is a major unmet need for patients living with chronic eye conditions. The results presented showcase the potential of the SpyGlass Drug Delivery Platform to be a game changer for glaucoma patients and all cataract surgeons.”
"Beyond our compelling clinical data, the SpyGlass technology is implanted utilizing standard surgical techniques that every cataract surgeon knows by heart. So often, new technology requires new surgical skills to learn, which can limit surgeon adoption. With SpyGlass technology, cataract surgeons will use their proven implantation techniques, making the potential adoption of SpyGlass’ Drug Delivery Platform three times greater than existing interventional glaucoma devices in market today," said SpyGlass Pharma CEO Patrick Mooney.